PNC-27
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
PNC-27 is an experimental anticancer peptide built around the p53 / HDM-2 axis. It fuses a fragment of the p53 protein (the residues that bind HDM-2) to a membrane-penetrating sequence, with the goal of killing cancer cells while sparing normal ones. It’s frequently lumped into “anti-aging / longevity” directories, but it’s really an anticancer / p53-restoration compound, not a longevity peptide proper.
What does it do in my body?
The peptide carries an HDM-2 binding domain that recognizes membrane-bound HDM-2 — a form of the protein that cancer cells display on their plasma membrane but normal cells largely don’t. PNC-27 binds it, then disrupts the membrane and the mitochondria, causing necrosis selectively in cancer cells. The selectivity claim — kills cancer cells, spares normal cells — is the whole pitch and recurs across the in-vitro literature.
How can it help me?
- Where the science stands: Strong in-vitro record, one human ex-vivo tissue study, one animal synergy study; zero randomized controlled trials
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No human safety data exists beyond one small ex-vivo tissue study and one human review of the mechanism class. There is no documented human side-effect profile to report.
Regulatory status: Research compound — not approved for human use. Tier D / encyclopedia-only: a genuinely interesting selective-cytotoxicity mechanism with real preclinical support, but no human clinical efficacy established and no place in a consumer-facing recommendation.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
None exists, and none should be implied. PNC-27 has no completed human-efficacy trials and no established dosing convention for human use. This is a research compound studied in cell culture and animal models, not a self-directed protocol candidate.
What should I avoid combining — and what's synergistic?
PNC-27 doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
PNC-27 is available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
An experimental anticancer peptide with a genuinely interesting selective-cytotoxicity mechanism and real preclinical support — but no completed human-efficacy trial and no place in a consumer recommendation. Often mislabeled as an “anti-aging” peptide when it’s really an anticancer / p53-restoration compound.
| Class | Experimental anticancer peptide built on the p53/HDM-2 axis, fused to a membrane-penetrating sequence |
| Mechanism (one line) | Binds membrane-bound HDM-2 on cancer cells, disrupting the membrane and mitochondria to cause selective necrosis |
| Evidence base | Strong in-vitro record, one human ex-vivo tissue study, one animal synergy study; zero randomized controlled trials |
| Safety record | No completed human-efficacy trials; safety in humans not established |
| Regulatory status | Research compound; not approved for human use |
What it is
PNC-27 is an experimental anticancer peptide built around the p53 / HDM-2 axis. It fuses a fragment of the p53 protein (the residues that bind HDM-2) to a membrane-penetrating sequence, with the goal of killing cancer cells while sparing normal ones. It’s frequently lumped into “anti-aging / longevity” directories, but it’s really an anticancer / p53-restoration compound, not a longevity peptide proper.
How it works
The peptide carries an HDM-2 binding domain that recognizes membrane-bound HDM-2 — a form of the protein that cancer cells display on their plasma membrane but normal cells largely don’t. PNC-27 binds it, then disrupts the membrane and the mitochondria, causing necrosis selectively in cancer cells. The selectivity claim — kills cancer cells, spares normal cells — is the whole pitch and recurs across the in-vitro literature.
What the research shows
The evidence is graded “moderate” (17 studies, claims 3 human), but the underlying body is overwhelmingly cell-based, with one ex-vivo human-tissue study and one animal synergy study. The credible, on-topic citations (all):
- Sarafraz-Yazdi E, et al. — Ann Clin Lab Sci 2015 ex-vivo case-series: PNC-27 inhibited growth and was cytotoxic to patient-derived epithelial ovarian cancer cells in a dose-dependent way. 26663795
- Alagkiozidis I, et al. — Ann Clin Lab Sci 2017: PNC-27 + paclitaxel showed a synergistic reduction in ovarian tumor growth in vivo. 28667027
- Pincus MR, et al. — Curr Pharm Des 2011 review — PNC-27/PNC-28 induce tumor-cell necrosis across multiple cancer types without harming normal cells. 21728981
- Krzesaj P, et al. — Ann Clin Lab Sci 2024 — PNC-27 binds membrane HDM-2 and disrupts mitochondria → cell necrosis. 38802154
- Thadi A, et al. — Anticancer Res 2020/2021 — selective necrosis of leukemia cells and colon-cancer stem cells via membrane HDM-2, sparing normal hematopoietic/epithelial cells. 32878773 · 33419797
There are zero randomized controlled trials and no completed human-efficacy trials. Source-integrity note: the directory profile this article draws from originally included two unrelated papers in its “key studies” table for PNC-27 (a Nigeria maternal-healthcare cohort and a Rome air-pollution study) — they have nothing to do with PNC-27 and are excluded here; treat any “3 human trials” count with caution.
Real-world protocol
None exists, and none should be implied. PNC-27 has no completed human-efficacy trials and no established dosing convention for human use. This is a research compound studied in cell culture and animal models, not a self-directed protocol candidate.
Side effects & management
No human safety data exists beyond one small ex-vivo tissue study and one human review of the mechanism class. There is no documented human side-effect profile to report.
Regulatory status
Research compound — not approved for human use. Tier D / encyclopedia-only: a genuinely interesting selective-cytotoxicity mechanism with real preclinical support, but no human clinical efficacy established and no place in a consumer-facing recommendation.